The collaboration between Verastem Oncology and GenFleet includes three discovery programmes. Credit: Kiattisak Th / Shutterstock.

Verastem Oncology has announced the dosing of the first patient with GFH375/VS-7375, a potent and selective oral KRAS G12D (ON/OFF) inhibitor, as part of a Phase I/II clinical trial in China.

GFH375/VS-7375 is identified as the lead discovery programme from the Verastem Oncology discovery and development partnership with GenFleet Therapeutics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase I part of the trial aims to evaluate the safety and efficacy of the therapy in patients with advanced KRAS G12D mutant solid tumours.

This oral inhibitor has shown promise in preclinical studies, demonstrating the potential to address a variety of solid tumours, including those with brain metastases.

The ongoing Phase I trial will involve approximately 20 hospitals across China and establish the recommended Phase II dose.

Subsequently, Phase II will further investigate GFH375/VS-7375’s efficacy and safety in treating advanced solid tumours such as colorectal cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The collaboration between Verastem Oncology and GenFleet includes three discovery programmes, with the KRAS G12D inhibitor being the foremost.

Verastem Oncology president and CEO Dan Paterson said: “In a short amount of time, we identified GFH375/VS-7375, a novel KRAS G12D (ON/OFF) inhibitor, as our lead discovery program last year and now the first patient has been dosed in the Phase I/II study by GenFleet in China.

“We look forward to leveraging the initial clinical dose escalation data to accelerate our development path in the US, as there are currently no FDA-approved KRAS G12D-targeted treatments despite the high prevalence of this KRAS mutation in various cancers, including pancreatic, colorectal, lung and uterine.”

Verastem Oncology holds exclusive options to license three compounds for development and commercialisation outside of GenFleet’s territories. This is contingent upon the achievement of Phase I milestones.